Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shRNA-GPC3 (short hairpin RNA targeting Glypican-3) is a gene-silencing tool used in molecular biology and oncology research to knock down the expression of Glypican-3 (GPC3). GPC3 is a cell-surface heparan sulfate proteoglycan that is highly expressed in embryonic tissues and various cancers, such as hepatocellular carcinoma (HCC) and lung squamous cell carcinoma (LUSC), but is minimally expressed in normal adult tissues. In laboratory models, shRNA-GPC3 is typically delivered via viral vectors (such as lentivirus) or plasmid transfection to study the functional role of GPC3 in tumor cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shRNA-GPC3.